4-1BB Antibodies in Oncology Clinical Trials: A Review
4-1BB is a transmembrane glycoprotein found on T lymphocytes, and signaling through 4-1BB activates and differentiates CD3+ and CD8+ T cells. The ability of 4-1BB to stimulate cytotoxic T-cell responses makes it a promising target for therapeutic cancer immunotherapy development. 4-1BB antibodies ha...
Saved in:
| Main Authors: | Robin Schwartz, Keerti Vajrala, Gerald S. Falchook |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2025-03-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-24-30 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01) -
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
by: Da-yan Zhang, et al.
Published: (2025-01-01) -
B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review
by: Meave Phipps, et al.
Published: (2025-04-01) -
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy
by: Pengchao Zhang, et al.
Published: (2025-03-01) -
4‐1BB and cytokines trigger human NK, γδ T, and CD8+ T cell proliferation and activation, but are not required for their effector functions
by: Laurent Vidard
Published: (2023-01-01)